Health Issues

Support for reauthorization of geriatrics workforce enhancement and academic career award programs (HR 4262, to reauthorize programs related to health professions education, and for other purposes, Energy & Commerce Committee draft for Title VII programs reauthorization; S.4110, EMPOWER for Health Act; and S.2699, Geriatrics Workforce Improvement Act). Support for research programs at the National Institute on Aging on drivers of chronic conditions, older adult medical complexity and Alzheimer's disease and related dementias. Support for amendments to S.1799/HR 3501, "Concentrating on High-Value Alzheimers Needs to Get to an End" legislation to provide for shared decision making, care planning and services, and primary care quality measures in connection with cognitive screening of Medicare beneficiaries; and monitoring of H.R. 6130, the Alzheimers Screening and Prevention (ASAP) Act of 2025.

Monitor the following: Site neutral related issues. Public Law 119-21, One Big Beautiful Bill Act, Medical Center related issues 340B related issues H.R.9504, Tax Exempt Hospital Transparency Act, Entirety

Blood and blood product reimbursement, recruitment of blood donors, blood donation awareness, infectious disease testing, access to blood in hospice and pre-hospital settings, licensure of blood centers

S.2292 - Over-the-Counter Monograph Drug User Fee Amendments H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments S.355 - FDA Modernization Act 3.0 H.R.2821 - FDA Modernization Act 3.0 H.R.3686 - SAFE Sunscreen Standards Act H.R.1 - One Big Beautiful Bill Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 S.2491 - SAFE Sunscreen Standards Act H.R.6868 - ACCESS Through OTC Innovation Act S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches (SMART OTC Act) H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.3122 - Better FDA Act of 2025 H.R.7366 - Dietary Supplement Regulatory Uniformity Act S.3788 - CLEAR LABELS Act - Activity related to Acetaminophen use - Nonprescription Drug Product with an Additional Condition for Nonprescription Use Rule H.R. 10336 - Dietary Supplement Innovation Act

Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA.

Issues pertaining to the Minority Fellowship Program. H.R. 10349, Emergency Responders Mental Health Training (EMT) Act, All Provisions.

- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 - Tribal Opioid Response Grant funding for FY27 - H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD)

Living Donor Protection Act (LDPA) S1522, HR4582,HR4583

H.R.2528, Association Health Plans Act; H.R.2571, Self-Insurance Protection Act; Issues related to health sector consolidation; Issues related to ERISA pre-emption; Issues related to employer sponsored health coverage; Issues related to telehealth; Issues related to association health plans; HCR - HR 9504 - Tax Exempt Hospital Transparency Act;

Issues related to the 340B Drug Pricing Program.